Mediwound reports second quarter 2023 financial results and provides company update

Escharex ® phase iii study protocol : fda/em a-aligned ; p atient enrollment commencing early 2024 ; two key research collaborations with wound industry leaders

MDWD Ratings Summary

MDWD Quant Ranking